Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 3;9(1):00199-2022.
doi: 10.1183/23120541.00199-2022. eCollection 2023 Jan.

COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

Spyros A Papiris  1 , Ilaria Campo  2 , Francesca Mariani  2 , Maria Kallieri  1 , Lykourgos Kolilekas  3 , Andriana I Papaioannou  1 , Efsun Gonca Chousein  4 , Erdogan Cetinkaya  4 , Francesco Bonella  5 , Raphael Borie  6 , Maria Kokosi  7 , Thomas Pickworth  8 , Maria Molina-Molina  9 , Mercè Gasa  9 , Elżbieta Radzikowska  10 , Justyna Fijolek  10 , Stéphane Jouneau  11 , Emmanuel Gomez  12 , Cormac McCarthy  13 , Elisabeth Bendstrup  14 , Wojciech J Piotrowski  15 , Rishi Pabary  16 , Alice Hadchouel  17 , Nathalie Coolen-Allou  18 , Tiago Alfaro  19 , Carlos Robalo Cordeiro  19 , Elvira-Markela Antonogiannaki  1 , Ioannis P Tomos  1 , Despoina Papakosta  20 , Theodoros Kontakiotis  20 , Panagiota Panagiotou  21 , Konstantinos Douros  22 , Andrea Schams  23 , Sara Lettieri  2 , Vassiliki Papaevangelou  22 , Christina Kanaka-Gantenbein  21 , Anna Karakatsani  1 , Stelios Loukides  1 , Ulrich Costabel  5 , Bruno Crestani  6 , Cliff Morgan  7 , Ryushi Tazawa  24 , Andrew Bush  16 , Matthias Griese  23 , Effrosyni D Manali  1
Affiliations

COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

Spyros A Papiris et al. ERJ Open Res. .

Abstract

Adult PAP patients experience similar #COVID19 rates to the general population, and high rates of hospitalisation and deaths, underscoring their vulnerability and the need for measures to prevent infection. The impact of iGM-CSF must be considered. https://bit.ly/3M0wKnZ.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S.A. Papiris reports grants, personal fees and nonfinancial support from La Roche Hoffman and Boehringer Ingelheim, and other support from Savara, outside the submitted work. Conflict of interest: F. Bonella reports grants and personal fees from Savara Pharma outside the submitted work. Conflict of interest: R. Borie has received consulting fees from Boehringer Ingelheim, Roche and Sanofi, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Roche, outside the submitted work; support for attending meetings and/or travel received from Boehringer Ingelheim, Roche and Chiesi outside the submitted work; and participation on a data safety monitoring or advisory board for Savara, outside the submitted work. Conflict of interest: M. Molina-Molina reports personal fees and grants from Esteve-Teijin, Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: E. Jouneau reports personal fees and other support from Actelion, AIRB, AstraZeneca, Bellerophon Therapeutics, Biogen, BMS, Boehringer Ingelheim, Chiesi, FibroGen, Galecto Biotech, Genzyme, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pharm-Olam, Pfizer, Pliant Therapeutics, F. Hoffmann-La Roche, Ltd, Sanofi and Savara-Serendex, outside the submitted work. Conflict of interest: C. McCarthy is a scientific advisory board member of Savara Inc. unrelated to this work and has not received any payment from Savara Inc. for any work to date. Conflict of interest: E. Bendstrup reports grants and personal fees from Boehringer Ingelheim and Hofmann la Roche, and personal fees from Galapagos, outside the submitted work. Conflict of interest: M. Griese has received grants or contracts from Boehringer Ingelheim, outside the submitted work; has participated on a data safety or advisory board for Boehringer Ingelheim, outside the submitted work; and is the Head of chILD-EU, outside the submitted work. Conflict of interest: E.D. Manali reports personal fees and nonfinancial support from La Roche Hoffman; grants, personal fees and nonfinancial support from Boehringer Ingelheim; and other support from Savara, all outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Potential relationship between granulocyte–macrophage colony-stimulating factor (GM-CSF) signalling, and the early and late inflammatory response to COVID-19. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; CSF2RA: granulocyte–macrophage colony-stimulating factor receptor subunit α.
See this image and copyright information in PMC

References

    1. Trapnell BC, Nakata K, Bonella F, et al. . Pulmonary alveolar proteinosis. Nat Rev Dis Primers 2019; 5: 16. doi:10.1038/s41572-019-0066-3 - DOI - PubMed
    1. Hadchouel A, Wieland T, Griese M, et al. . Biallelic mutations of methionyl-tRNA synthetase cause a specific type of pulmonary alveolar proteinosis prevalent on Réunion Island. Am J Hum Genet 2015; 96: 826–831. doi:10.1016/j.ajhg.2015.03.010 - DOI - PMC - PubMed
    1. Bush A, Pabary R. Pulmonary alveolar proteinosis in children. Breathe (Sheff) 2020; 16: 200001. doi:10.1183/20734735.0001-2020 - DOI - PMC - PubMed
    1. Tazawa R, Hamano E, Arai T, et al. . Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005; 171: 1142–1149. doi:10.1164/rccm.200406-716OC - DOI - PubMed
    1. Tazawa R, Trapnell BC, Inoue Y, et al. . Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181: 1345–1354. doi:10.1164/rccm.200906-0978OC - DOI - PMC - PubMed

LinkOut - more resources